1. Introduction {#sec1-ijms-21-03743}
===============

Oxidative stress reflects a disturbance in the balance between the production and accumulation of reactive oxygen species (ROS), and an overproduction of ROS has negative consequences for cell physiology \[[@B1-ijms-21-03743]\]. When ROS concentration is in excess, oxidative damage to proteins, lipids, and DNA occurs, thus causing structural and functional cellular changes. DNA damage is usually repaired primarily via the base excision repair pathway, and oxidized products are excreted in urine \[[@B2-ijms-21-03743]\]. 8-hydroxy-2-deoxyguanosine (8-OHdG) is one of the most widely studied oxidized metabolites and is considered as a biomarker for oxidative damage of DNA \[[@B3-ijms-21-03743],[@B4-ijms-21-03743]\]. The formation of 8-OHdG by oxygen radicals was first reported in 1984 by Kasai and Nishimura \[[@B5-ijms-21-03743]\].

The interaction of the hydroxyl radical, the most important oxygen-free radical, with the nucleobases of the DNA strand, such as guanine, leads to the formation of 8-OHdG \[[@B6-ijms-21-03743]\] ([Figure 1](#ijms-21-03743-f001){ref-type="fig"}).

Some diseases, such as cardiovascular or chronic obstructive pulmonary diseases (COPD), have been associated with excessive concentrations of 8-OHdG \[[@B7-ijms-21-03743],[@B8-ijms-21-03743]\]. 8-OHdG levels also increase due to smoking, aging, or occupational exposure to physical, chemical, or biological substances \[[@B9-ijms-21-03743],[@B10-ijms-21-03743]\].

A recent study suggested that 8-OHdG had high intraclass correlation coefficients (0.96), reproducible measurements, and low coefficients of variation and was the most suitable biomarker of oxidative stress in spot urine samples \[[@B11-ijms-21-03743]\]. Concentrations of urinary oxidative stress biomarkers have been proposed as an effect biomarker to survey populations exposed to xenobiotics such as particulates, oxidizing agents, and lately, engineered nanomaterials \[[@B12-ijms-21-03743],[@B13-ijms-21-03743]\].

Measuring urinary 8-OHdG has some advantages as it is very stable in urine \[[@B14-ijms-21-03743]\], it is noninvasive, and its excretion is likely to reflect the oxidative DNA damage \[[@B15-ijms-21-03743]\] and can be assessed by two main analytical techniques: mass-based methods (using either gas (GC) or liquid (LC) chromatography) and immunological methods. Another source of 8-OHdG in urine is DNA polymerase-dependent incorporation of 8-oxodGTP from the nucleotide pool \[[@B16-ijms-21-03743]\]. Chromatographic methods are considered to be the gold standard; however, immunological techniques, which are less costly and time-consuming, are widely used because enzyme-linked immunosorbent assay (ELISA) kits have been developed for rapid detection and quantification of 8-OHdG \[[@B14-ijms-21-03743],[@B17-ijms-21-03743]\].

A background range for 8-OHdG has been reported in different studies for healthy persons \[[@B11-ijms-21-03743],[@B18-ijms-21-03743],[@B19-ijms-21-03743],[@B20-ijms-21-03743]\]. However, these studies reported a wider range of values, making the identification of background cut-off values challenging.

Therefore, the systematic review and meta-analyses of the reported values appears the most appropriate approach to bypass this issue. Our objective was to assess background ranges for urinary 8-OHdG concentrations in healthy adults.

2. Results {#sec2-ijms-21-03743}
==========

Chemical methods were used in 44 of the 128 study subgroups, and immunological techniques were used in 84 ([Table 1](#ijms-21-03743-t001){ref-type="table"}). We decided to stratify the subgroups by body mass index (BMI), gender, and smoking status reported.

2.1. Descriptive Results {#sec2dot1-ijms-21-03743}
------------------------

We retrieved 1246 articles, included 84 articles, and considered 129 study subgroups ([Figure 2](#ijms-21-03743-f002){ref-type="fig"}, [Table 2](#ijms-21-03743-t002){ref-type="table"}, [Table 3](#ijms-21-03743-t003){ref-type="table"}, [Table 4](#ijms-21-03743-t004){ref-type="table"} and [Table 5](#ijms-21-03743-t005){ref-type="table"}) in the quantitative synthesis, which we stratified by main quantification techniques: immunological and chemical methods. For subgroups evaluated with the chemical methods, 31 studies had participants with a mean BMI between 18 and 25 (14 study subgroups of nonsmokers and 2 study subgroups of smokers) ([Figure 3](#ijms-21-03743-f003){ref-type="fig"}, [Table 2](#ijms-21-03743-t002){ref-type="table"}). Nine studies had participants with a mean BMI \> 25 (three study subgroups of nonsmokers and two study subgroups of smokers) ([Figure 4](#ijms-21-03743-f004){ref-type="fig"}, [Table 3](#ijms-21-03743-t003){ref-type="table"}). The mean BMI was unknown for four study subgroups.

For subgroups analyzed with immunological techniques, 47 studies had participants with a mean BMI between 18 and 25 (24 study subgroups of nonsmokers, no study subgroups of smokers and 6 study subgroups with unknown smoking status) ([Figure 5](#ijms-21-03743-f005){ref-type="fig"}, [Table 4](#ijms-21-03743-t004){ref-type="table"}). Twenty-six studies had participants with a mean BMI \> 25 (13 study subgroups of nonsmokers and 6 study subgroups of smokers) ([Figure 6](#ijms-21-03743-f006){ref-type="fig"}, [Table 5](#ijms-21-03743-t005){ref-type="table"}). The mean BMI was unknown for 11 study subgroups. [Supplementary material](#app1-ijms-21-03743){ref-type="app"} provides detailed information on the criteria used for the quality assessment (S1) and on the quality level of each included study subgroup (S2). Overall, two study subgroups (1.8%) were classified as low quality, 66 (58.4%) as moderate quality, and 45 study subgroups (39.8%) were of high quality.

2.2. Meta-Analysis Results {#sec2dot2-ijms-21-03743}
--------------------------

As between-study heterogeneity was much larger than the between-subject heterogeneity, we decided to use a mixed model with study ID as a random effect. The IQR of subgroup-specific GM in subgroups with a mean BMI ≤ 25 with 8-OHdG measured using chemical methods was 3 to 5.5 ng/mg creatinine ([Table 1](#ijms-21-03743-t001){ref-type="table"}). IQR of subgroup-specific GM in subgroups with a mean BMI \> 25 measured using immunological methods was 5.9 to 19.8 ng/mg creatinine ([Table 1](#ijms-21-03743-t001){ref-type="table"}).

We compared urinary 8-OHdG concentrations by smoking status within the study subgroups analyzed with chemical techniques and found that for study subgroups with mean BMI ≤ 25, smokers were 2.84 (\[2.56, 3.16\], *p* \< 0.0001) times greater compared to nonsmoker study subgroups.

For study subgroups with mean BMI \> 25, smokers were 1.61 (\[1.17, 2.23\], *p* = 0.004) times greater compared to the nonsmoker study.

No consistent effects of BMI and gender were observed in our mixed model either for chemical or immunological methods. Gender and BMI seem to not influence urinary 8-OHdG concentrations.

3. Discussion {#sec3-ijms-21-03743}
=============

3.1. Interpretation of Findings {#sec3dot1-ijms-21-03743}
-------------------------------

We found that urinary 8-OHdG concentrations in smokers were greater than in nonsmokers when analysis was conducted with chemical techniques. However, in the population with mean BMI between 18 and 25, this finding was mainly due to one study \[[@B32-ijms-21-03743]\] and needs to be confirmed. The absence of BMI effect on 8-OHdG in urine is in line with data from Lee et al. 2010 \[[@B93-ijms-21-03743]\].

The IQR range for 8-OHdG in urine given in this meta-analysis is in line with two other studies trying to define reference values for the Italian population (female: 3.25--6.85 ng/mg creatinine; male: 2.9--5.5 ng/mg creatinine) \[[@B94-ijms-21-03743]\]. The absence of gender effect observed for 8-OHdG in this study is in line with data from the Italian population \[[@B94-ijms-21-03743]\] but in contradiction with two others \[[@B93-ijms-21-03743],[@B95-ijms-21-03743]\].

The analysis of the data was difficult due to the diversity in study design, analytical methods (chemical or immunoassay techniques), statistical analysis, and data presentation in studies included.

3.2. Quantification of 8-OHdG {#sec3dot2-ijms-21-03743}
-----------------------------

The heterogeneity in techniques used to quantify urinary 8-OHdG makes it more difficult to compare data between laboratories.

Chemical techniques are superior to immunological techniques due to their sensitivity and specificity \[[@B14-ijms-21-03743],[@B96-ijms-21-03743]\]. Chemical techniques require expensive instruments and trained users, but we recommend using chemical quantification methods as standard methods for future studies of biomonitoring.

3.3. Lack of Homogeneity in Data Collection and Reporting {#sec3dot3-ijms-21-03743}
---------------------------------------------------------

Most studies used spot urine samples for 8-OHdG rather than 12- or 24-h collection. However, 8-OHdG levels showed fluctuation during the day under oxidative states \[[@B97-ijms-21-03743]\], but good correlations have been observed between levels of 8-OHdG in spot morning urine and levels of 8-OHdG in the 24-h urinary collection \[[@B14-ijms-21-03743]\]. Therefore, we included studies reporting spot morning urine, 12- or 24-h urinary samples. The first morning urine void is particularly valuable because it provides a time average for biomarker concentrations that may occur during the hours of sleep (approximately 8 h) and is also relatively free of dietary, physical, and environmental exposures \[[@B15-ijms-21-03743]\]. A significant increase in time in the urinary 8-OHdG during the first part of the day was recently reported among smokers \[[@B15-ijms-21-03743]\]. To make it easier to compare results between studies, we recommend collecting spot morning urine.

3.4. Limitations {#sec3dot4-ijms-21-03743}
----------------

We confirm that smokers have a significantly greater concentration of urinary 8-OHdG, as has been previously reported in the literature. The concentration differences need to be quantified, but with only a few studies in smokers available, this cannot be done at the present time.

We emphasize here that the values we report are for a healthy population. We were not able to analyze parameters previously reported to influence 8-OHdG concentrations such as occupation, pregnancy, special diet, vitamin, and physical activity due to the limited number of studies with such data.

3.5. Recommendations {#sec3dot5-ijms-21-03743}
--------------------

The fluctuation in urine flow rate could in fact affect the assessment of urinary 8-OHdG. The urinary 8-OHdG concentrations need to be normalized by urinary creatinine concentrations for healthy adults. Different studies indicated a correlation between excretion of creatinine and 8-OHdG \[[@B94-ijms-21-03743],[@B95-ijms-21-03743]\]. In addition, normalization with creatinine for spot urine can be considered as a surrogate for the 24-h excretion of 8-OHdG \[[@B94-ijms-21-03743],[@B98-ijms-21-03743]\].

To reach consensual background of urinary 8-OHdG values, harmonization of the unit (ng/mg creatinine) is needed. Harmonization of the statistical reporting of the results is also recommended (geometric means (GM) and geometric standard deviations (GSD)). We suggest reporting the median and the 1st and 3rd quartile as GSDs are not easy to interpret.

4. Materials and Methods {#sec4-ijms-21-03743}
========================

We established a standardized protocol for systematic review and meta-analysis for a set of biomarkers of oxidative stress. This protocol was registered in the International Prospective Register of Systematic Reviews (registration number CRD 42020146623) \[[@B99-ijms-21-03743]\] and described in detail by Hemmendinger et al. \[[@B100-ijms-21-03743]\]. The protocol was then adapted for each biomarker depending on the biological matrix focused, here the urinary 8-OHdG. The methods and results of this study are reported following recommendations from Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations \[[@B101-ijms-21-03743],[@B102-ijms-21-03743]\].

4.1. Literature Search {#sec4dot1-ijms-21-03743}
----------------------

The search strategy was done with a medical librarian. The MeSH (Medical Subject Headings) terms from the PubMed database and free text words were combined. The complete search string was: ("Smoking/urine"\[Mesh\] OR "Urine"\[Mesh\] OR Urine\*\[tiab\] OR Urinary\[tiab\] OR Urinal\*\[tiab\]) AND ("8-oxo-7-hydrodeoxyguanosine"\[Supplementary Concept\] OR 8-OHdg\[tw\] OR 8ohdg\[tw\] OR 8-oh-dg\[tw\] OR 8-ohg\[tw\] OR 8-OH-2dG\[tw\] OR 8-hydroxydeoxyguanosine\[tw\] OR 8-hydroxyguanine\[tw\] OR 8-hydroxy-g\[tw\] OR 8-hydroxy-dg\[tw\] OR 8-hydroxy-guanine\[tw\] OR 8-hydroxy-2-deoxyguanosine\[tw\]) NOT (("Child"\[Mesh\] OR "Infant"\[Mesh\] OR "Adolescent"\[MeSH\]) NOT "adult"\[MeSH\]) NOT (animals\[mh\] NOT humans\[mh\]).

4.2. Study Selection {#sec4dot2-ijms-21-03743}
--------------------

The search was performed on 7 May 2019. Rayyan \[[@B103-ijms-21-03743]\], a systematic review web application, was used for title and abstract screening. We selected the studies in a stepwise process as depicted in [Figure 6](#ijms-21-03743-f006){ref-type="fig"}. To be included in the analysis, a study had to be in English and to provide urinary 8-OHdG concentrations in healthy adults (ages 18---no upper age limit) populations. We excluded non-human studies, in vitro studies, reviews, letters, expert opinions, and editorials. We read the eligible articles in depth, and only studies with original data from healthy (no known disease) adult populations were included in the statistical analysis. All techniques used for the quantification of 8-OHdG were included and classified accordingly. We excluded studies with coefficient variation \<10% or \>200%. We also excluded data suspected to have unit or reported value mistakes (more than three orders of magnitude higher than the median levels).

4.3. Data Extraction {#sec4dot3-ijms-21-03743}
--------------------

We extracted the following information: first author name, publication year, study type, country, analytic method, sample time, sample size, gender, mean age, mean BMI, smoking status, season, occupation, pregnancy, diet, vitamin, exercise, outcome (8-OHdG concentration), references, and article DOI. We extracted all subgroup-specific data when data on several subgroups were available in a given paper. Then, we excluded all subgroups selected based on disease status (e.g., cardiovascular disease) and all subgroups selected based on an exposure status (e.g., bus drivers). If data on the same subgroup were reported for different times (e.g., different seasons), only the data at the time of participant inclusion were included. In a third round, we excluded duplicate data (e.g., control population reported in more than one study) and retained the most complete and the most recent study.

4.4. Statistical Analysis {#sec4dot4-ijms-21-03743}
-------------------------

First, we analyzed the values of urinary 8-OHdG measured in original studies in view of establishing the background ranges using meta-analysis. Measured values were generally log-normally distributed. We therefore computed geometric means (GM) and geometric standard deviations (GSD) as the basis for the meta-analysis or equivalently $muL = \ln\left( {GM} \right)$ and $sdL = \ln\left( {GSD} \right)$. Further details on the data treatment and analyses are available elsewhere \[[@B104-ijms-21-03743]\].

We could not compute standard errors on the geometric (or arithmetic) scale when neither standard deviation (SD), GSD, IQR, nor confidence interval (CI) were reported. As a consequence, we excluded these studies from the meta-analysis. We converted all the concentration values to the same units (ng/mg creatinine) before computing GM and GSD. We used 113.12 g/mol for the molecular weight for creatinine and 283.24 g/mol for 8-OHdG. We regrouped the data according to analytical techniques used; immunological techniques and chemical techniques. The data were analyzed separately.

We followed standard practice in meta-analysis \[[@B105-ijms-21-03743]\] and represent the data as forest plots including the I-squared. This is an estimate of the between-study heterogeneity in percentage. If the between-study heterogeneity is much larger than the between-subject heterogeneity, then I^2^ is large. In this case, any attempt of obtaining a background value for individual participants will not be valid. In our case, a mixed model with study ID as a random effect is a more relevant analysis model. This yields results on the study subgroup level rather than at the individual level. Data management and statistical analyses were performed in STATA version 16 software.

5. Conclusions {#sec5-ijms-21-03743}
==============

We report pooled GM values for urinary 8-OHdG in healthy adults, separately for chemical and immunological methods. We observed a significant positive association between smoking status and urinary 8-OHdG concentrations when measured by chemical analysis. No gender effect was shown. Urinary 8-OHdG can potentially be used to quantify excess oxidative stress due to external exposures when background values have been established in different populations. We recommend adjusting urine samples with creatinine, quantifying 8-OHdG with chemical methods, and reporting results as median and quartiles. Comparing values across studies will then be feasible.

Supplementary Materials can be found at <https://www.mdpi.com/1422-0067/21/11/3743/s1>.
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ijms-21-03743-t001_Table 1

###### 

Summary of geometric mean urinary 8-OHdG concentrations (ng/mg creatinine) in subgroups of healthy adult (18+ years) participants.

  ------------------------------------------------------------------------------------------------
                  BMI ≤ 25          BMI \> 25                                                
  --------------- ----------------- ------------ ------------- ---------------- ------------ -----
  Chemical        3.9 \*\           Nonsmokers   4.3           2.8\             Nonsmokers   2.5
                  (3--5.5)\                                    (2.4--3.5)\                   
                  (*n* \*\* = 31)                              (*n* = 9)                     

  (*n* = 14)      (2.9--5.5)        (*n* = 3)    (1.9--2.8)                                  

  Smokers         22.2              Smokers      4.0                                         

  (*n* = 2)       (3--41.4)         (*n* = 2)    (3.5--4.5)                                  

  Immunological   9.0\              Nonsmokers   11.5          7.7\             Nonsmokers   9.3
                  (5.9--19.8)\                                 (5.8 -- 10.9)\                
                  (*n* = 47)                                   (*n* = 26)                    

  (*n* = 24)      (5.9--21.6)       (*n* = 13)   (7.8--14.7)                                 

  Smokers         NA                Smokers      6.0                                         

  (*n* = 0)                         (*n* = 6)    (5.4--7)                                    
  ------------------------------------------------------------------------------------------------

\* Median (IQR: 25%--75%); \*\* Number of included study subgroups; NA: Not Available.

ijms-21-03743-t002_Table 2

###### 

References for urinary 8-OHdG concentrations and computed GM (ng/mg creatinine) measured with chemical techniques in healthy (mean BMI ≤ 25 and no known disease), adult (18+ years) participants.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                  Study Group                           Analytic Method                  Sample       Country     Sample Size   Mean Age   Female   Male   Smoking Status   Mean BMI   AM                GM             IQR           Range         Median   CI           Units\                Computed GM (ng/mg Creatinine)   GSD
                                                                                                                                                                                                                                                                                     (8-OHdG/Creatinine)                                    
  -------------------------- ------------------------------------- -------------------------------- ------------ ----------- ------------- ---------- -------- ------ ---------------- ---------- ----------------- -------------- ------------- ------------- -------- ------------ --------------------- -------------------------------- -----
  \[[@B21-ijms-21-03743]\]   Control group                         HPLC                             spot urine   China       497           42.48      113      384    50%              23.72      4.47 ± 1.26 \*                                                                     nmol/mmol             11                               1

  \[[@B22-ijms-21-03743]\]   Control group                         HPLC-MS/MS                       spot urine   China       106           31.62      0        106    52.8%            23.79      3 ± 1.08 \*                                                                        μg/g                  3                                1

  \[[@B23-ijms-21-03743]\]   Selenium group baseline value         HPLC with EC detection           spot urine   USA         17            30.7       0        17     0%               24.2       3.16 ± 1.28 \*                                                                     ng/mg                 3                                1

  \[[@B24-ijms-21-03743]\]   Baseline value                        UPLC-MS-MS in positive EI mode   spot urine   Belgium     48            40         3        45     31.2%            24.2       10.76 ± 2.83 \*                                7.05--20.92                         μg/g                  10                               1

  \[[@B25-ijms-21-03743]\]   Men baseline                          HPLC                             spot urine   Japan       2370          60.7       0        2370   24.9%            23.6                         3.7 ± 1.6 \*                                                     ng/mg                 4                                2

  \[[@B25-ijms-21-03743]\]   Women baseline                        HPLC                             spot urine   Japan       4052          60.2       4052     0      4.7%             22.2                         4.1 ± 1.7 \*                                                     ng/mg                 4                                2

  \[[@B26-ijms-21-03743]\]   Baseline value                        LC-MS/MS                         spot urine   Taiwan      58            23.84      0        58     51.7%            24.55                                       2.63--11.54                 4.42                  µg/g                  16                               2

  \[[@B27-ijms-21-03743]\]   Service staff group                   HPLC                             spot urine   China       67            24.8       0        67     0%               23.2                                                                    1.4      0.9--1.8     μmol/mol              2                                3

  \[[@B28-ijms-21-03743]\]   All population                        HPLC                             spot urine   Japan       503           42.4       209      294    27.4%            22.5                                        2.37--4.03    0.8--10.0     3.01                  μg/g                  3                                1

  \[[@B29-ijms-21-03743]\]   Baseline value                        HPLC                             spot urine   Korea       102           55         102      0      0%               24.1       6.5 ± 3.9 \*                                                                       μg/g                  6                                2

  \[[@B30-ijms-21-03743]\]   Control group                         HPLC                             spot urine   Japan       805           40.3       0        805    46.7%            23.7       3.79 ± 1.44 \*                                                                     ng/mg                 4                                1

  \[[@B31-ijms-21-03743]\]   Baseline value                        GC-MS                            spot urine   Singapore   24            22.8       NA       NA     0%               21.6       2.02 ± 1.12 \*                                                                     µmol/mol              5                                2

  \[[@B32-ijms-21-03743]\]   Non smoker group baseline             HPLC with EC detection           24 h urine   China       30            21.5       0        30     0%               22.8       6.3 ± 0.5 \*\*                                                                     µmol/mol              14                               2

  \[[@B32-ijms-21-03743]\]   Smoker group baseline                 HPLC with EC detection           24 h urine   China       60            21.8       0        60     100%             22.6       18 ± 1 \*\*                                                                        µmol/mol              41                               2

  \[[@B33-ijms-21-03743]\]   Participants without stroke           LC--MS/MS                        spot urine   Taiwan      131           64.9       57       74     50%              22.9                                        8.3--22.8                   13                    μg/g                  13                               2

  \[[@B34-ijms-21-03743]\]   Male baseline                         HPLC-EC                          spot urine   Japan       79            47.9       0        79     0%               22.3       2.81 ± 1.07 \*                                                                     μg/g                  3                                2

  \[[@B34-ijms-21-03743]\]   Female baseline                       HPLC-EC                          spot urine   Japan       16            46.7       16       0      0%               20.6       3.04 ± 1.42 \*                                                                     μg/g                  3                                1

  \[[@B35-ijms-21-03743]\]   Women baseline                        HPLC                             spot urine   Japan       37            28--57     37       0      5.4%             21.5                                        3.2--5.2                    3.9                   μg/g                  4                                1

  \[[@B35-ijms-21-03743]\]   Non smoking men group baseline        HPLC                             spot urine   Japan       87            28--57     0        87     0%               24.2                                        2.9--4.7                    3.6                   μg/g                  4                                1

  \[[@B36-ijms-21-03743]\]   Baseline value                        HPLC with an EC detector         spot urine   Japan       23            46.8       11       12     100%             23.6                         3.02                                                2.24--4.07   ng/mg                 5                                1

  \[[@B37-ijms-21-03743]\]   Control group                         LC--MS/MS                        spot urine   Taiwan      125           34.1       0        125    0%               22.8                         4.1 ± 2.1 \*                                                     μg/g                  4                                2

  \[[@B38-ijms-21-03743]\]   Control group                         HPLC-MS/MS                       spot urine   China       185           40.4       124      61     0%               24.4                         5.5 ± 2.2 \*                                                     µg/g                  6                                2

  \[[@B39-ijms-21-03743]\]   Control group                         LC EC                            spot urine   India       135           41.31      0        135    0%               22.38      3.57 ± 0.63 \*                                                                     μmol/mol              9                                1

  \[[@B40-ijms-21-03743]\]   All population                        HPLC                             spot urine   Japan       6517          60.3       4064     2453   12.6%            22.7                         3.9 ± 1.6 \*                                                     ng/mg                 4                                2

  \[[@B41-ijms-21-03743]\]   Placebo group end of study            LC-MS/MS                         spot urine   USA         12            69         6        6      0%               25         2 ± 0.2 \*\*                                                                       µmol/mol              5                                1

  \[[@B41-ijms-21-03743]\]   Tart cherryjuice group end of study   LC-MS/MS                         spot urine   USA         12            69         6        6      0%               25         1.8 ± 0.1 \*\*                                                                     µmol/mol              4                                1

  \[[@B42-ijms-21-03743]\]   Male group                            LC-MS/MS                         spot urine   China       69            37.83      0        69     43.5%            24.1       4.55 ± 4.44 \*                                                                     μg/g                  3                                2

  \[[@B42-ijms-21-03743]\]   Female group                          LC-MS/MS                         spot urine   China       23            38.55      23       0      0%               22.1       4.34 ± 3.85 \*                                                                     μg/g                  3                                2

  \[[@B43-ijms-21-03743]\]   Control group                         LC--MS/MS                        spot urine   Taiwan      129           51.7       39       90     27.9%            24.6       4.3 ± 0.5 \*\*                                                                     ng/mg                 3                                3

  \[[@B44-ijms-21-03743]\]   Men group                             HPLC                             spot urine   Japan       196           44.4       0        196    43.9%            23.8       3.3 ± 1.1 \*                                                                       µg/g                  3                                1

  \[[@B44-ijms-21-03743]\]   Women group                           HPLC                             spot urine   Japan       136           40.4       136      0      2.9%             21         3.3 ± 1.1 \*                                                                       µg/g                  3                                1
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* SD, \*\* SEM.

ijms-21-03743-t003_Table 3

###### 

References for urinary 8-OHdG concentrations measured and computed GM (ng/mg creatinine) with chemical techniques in healthy (mean BMI \> 25 and no known disease), adult (18+ years) participants.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                  Study Group                  Analytic Method          Sample       Country   Sample Size   Mean Age   Female   Male   Smoking Status   Mean BMI     AM                IQR        Median   Units\                Computed GM\         GSD
                                                                                                                                                                                                                       (8-OHdG/Creatinine)   (ng/mg Creatinine)   
  -------------------------- ---------------------------- ------------------------ ------------ --------- ------------- ---------- -------- ------ ---------------- ------------ ----------------- ---------- -------- --------------------- -------------------- -----
  \[[@B45-ijms-21-03743]\]   Elderly low expose group     LC--MS/MS                spot urine   Taiwan    71            66.36      36       35     9.9%             26.36        3.16 ± 4.07 \*                        μg/g                  3                    2

  \[[@B23-ijms-21-03743]\]   Placebo group                HPLC with EC detection   spot urine   USA       19            31.1       0        19     0%               25.2         4.18 ± 4.78 \*                        ng/mg                 3                    2

  \[[@B46-ijms-21-03743]\]   Control group                LC/MS/MS                 spot urine   Taiwan    168           43.2       NA       NA     34%              26.4         10.61 ± 7.77 \*                       µmol/mol              21                   2

  \[[@B47-ijms-21-03743]\]   Control group                HPLC                     spot urine   China     31            38.7       0        31     19.4%            ≤24 38.7%\                     1.0--4.0   1.3      µmol/mol              3                    3
                                                                                                                                                                    \>24 61.3%                                                                                    

  \[[@B48-ijms-21-03743]\]   Control non smoker group     HPLC--ECD                spot urine   Turkey    19            54.8       3        16     0%               29.1         2.1 ± 1 \*                            μg/g                  2                    1

  \[[@B48-ijms-21-03743]\]   Control ex-smoker group      HPLC--ECD                spot urine   Turkey    21            57.5       3        18     0%               27.2         2.6 ± 0.8 \*                          μg/g                  2                    2

  \[[@B48-ijms-21-03743]\]   Control smoker group         HPLC-- ECD               spot urine   Turkey    24            51.1       4        20     100%             26.5         4.2 ± 2.8 \*                          μg/g                  3                    2

  \[[@B35-ijms-21-03743]\]   Smoking men group baseline   HPLC                     spot urine   Japan     40            28--57     0        40     100%             25.1                           3.6--5.6   4.5      μg/g                  4                    1

  \[[@B49-ijms-21-03743]\]   Control group baseline       HPLC                     spot urine   USA       20            39         20       0      50%              29           2.8 ± 1.7 \*                          µg/g                  2                    2
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* SD.

ijms-21-03743-t004_Table 4

###### 

References for urinary 8-OHdG concentrations measured and computed GM (ng/mg creatinine) with immunological techniques in healthy (mean BMI ≤ 25 and no known disease), adult (18+ years) participants.

  Reference                  Study Group                                           Sample       Country    Sample Size   Mean Age   Female   Male   Smoking Status   Mean BMI    AM                    GM                IQR          Range          Median   CI           Units (8-OHdG/Creatinine)   Computed GM (ng/mg Creatinine)   GSD
  -------------------------- ----------------------------------------------------- ------------ ---------- ------------- ---------- -------- ------ ---------------- ----------- --------------------- ----------------- ------------ -------------- -------- ------------ --------------------------- -------------------------------- -----
  \[[@B50-ijms-21-03743]\]   Healthy control group                                 24 h urine   Thailand   30            41.43      19       11     NA               22.56       4.32 ± 4.93 \*                                                                            μg/g                        3                                2
  \[[@B51-ijms-21-03743]\]   Healthy control group                                 24 h urine   Thailand   30            41.43      19       11     NA               22.56       5.27 ± 2.77 \*                                                                            μg/g                        5                                2
  \[[@B52-ijms-21-03743]\]   Control group                                         spot urine   China      35            60         15       20     0%               22.9        11.9 ± 4.9 \*                                                                             ng/mg                       11                               1
  \[[@B53-ijms-21-03743]\]   Control group                                         spot urine   Korea      416           64.4       92       324    28.1%            23.7                              5.06                                                   4.55--5.62   μg/g                        5                                2
  \[[@B54-ijms-21-03743]\]   Control group                                         spot urine   Korea      140           68.8       32       108    65.5%            22.46                             4.88                                                   4.43--5.38   μg/g                        5                                1
  \[[@B55-ijms-21-03743]\]   Healthy young group                                   24 h urine   Canada     12            22.8       0        12     0%               25          5333 ± 1191 \*                                                                            ng/g                        5                                1
  \[[@B56-ijms-21-03743]\]   Apple group final value                               spot urine   China      13            62.8       3        10     0%               24.2        824.41 ± 343.66 \*                                                                        ng/mmol                     7                                1
  \[[@B56-ijms-21-03743]\]   Pomegranate group final value                         spot urine   China      13            64.1       3        10     0%               23          651.57 ± 332.44 \*                                                                        ng/mmol                     5                                2
  \[[@B57-ijms-21-03743]\]   placebo group baseline value                          spot urine   China      150           51.58      92       58     41.3%            23.8                              60.89 ± 1.62\*                                58.19                 ng/mg                       61                               2
  \[[@B57-ijms-21-03743]\]   Baseline line value Low FA group                      spot urine   China      145           48.9       87       58     33.8%            24.5                              55.48 ± 1.74 \*                               53.51                 ng/mg                       55                               2
  \[[@B57-ijms-21-03743]\]   Baseline value high FA group                          spot urine   China      143           48.66      94       49     30.1%            24.6                              55.81 ± 1.72 \*                               54.73                 ng/mg                       56                               2
  \[[@B58-ijms-21-03743]\]   Control group                                         24 h urine   Japan      15            40         6        9      0%               23.2        9.7 ± 4.6 \*                                                                              ng/mg                       9                                2
  \[[@B59-ijms-21-03743]\]   Control group I                                       spot urine   China      20            25.55      17       3      0%               19.74       10.68 ± 1.07 \*\*                                                                         ng/mg                       10                               2
  \[[@B59-ijms-21-03743]\]   Control group II                                      spot urine   China      20            24.5       15       5      0%               20.09       11.96 ± 0.73 \*\*                                                                         ng/mg                       12                               1
  \[[@B60-ijms-21-03743]\]   Male group                                            spot urine   Japan      195           41.7       0        195    49.7%            23.6        9.35 ± 3.66 \*                                                                            ng/mg                       9                                1
  \[[@B60-ijms-21-03743]\]   Female group                                          spot urine   Japan      194           41.7       194      0      29.9%            22.1        10.97 ± 5 \*                                                                              ng/mg                       10                               2
  \[[@B61-ijms-21-03743]\]   Non MS group                                          spot urine   Japan      638           40.8       385      253    27.3%            22.3        9.28 ± 4.15 \*                                                                            ng/mg                       8                                2
  \[[@B62-ijms-21-03743]\]   Male control                                          spot urine   Pakistan   34            39.7       0        34     0%               19.85       24.5 ± 6.6 \*                                        11.08--33.85   25.72                 ng/mg                       26                               1
  \[[@B62-ijms-21-03743]\]   Female control                                        spot urine   Pakistan   32            39.52      32       0      0%               20.83       24.5 ± 6.33 \*                                       11.1--33.85    24.47                 ng/mg                       24                               1
  \[[@B63-ijms-21-03743]\]   Control group                                         spot urine   Pakistan   34            39.7       0        34     0%               20.9        24 ± 4 \*                                            9--30          25                    ng/mg                       25                               1
  \[[@B64-ijms-21-03743]\]   Control group                                         spot urine   Pakistan   34            37         0        34     0%               20.8        25.8 ± 7 \*                                          9.1--33.9      27.9                  ng/mg                       28                               1
  \[[@B65-ijms-21-03743]\]   Pregnant women                                        spot urine   Korea      261           29.6       261      0      0%               21          20.8 ± 14.2 \*                                                                            µg/g                        17                               2
  \[[@B66-ijms-21-03743]\]   Control group baseline                                spot urine   UK         32            31.7       15       17     0%               22.4        21.6 ± 12.6 \*                                                                            ng/mg                       19                               2
  \[[@B66-ijms-21-03743]\]   Test group baseline                                   spot urine   UK         32            31.7       15       17     0%               22.4        24 ± 13.3 \*                                                                              ng/mg                       21                               2
  \[[@B67-ijms-21-03743]\]   Control group                                         spot urine   Turkey     20            40.7       10       10     NA               22.52       7.84 ± 7.04 \*                                                                            ng/mg                       6                                2
  \[[@B68-ijms-21-03743]\]   Control group                                         spot urine   Japan      108           23         0        108    NA               22.5        10.4 ± 3.2 \*                                                                             ng/mg                       10                               1
  \[[@B69-ijms-21-03743]\]   Non exposed group                                     spot urine   Iran       43            35.58      0        43     21%              19--24      54.16 ± 26.98 \*                                                                          ng/mg                       48                               2
  \[[@B70-ijms-21-03743]\]   Control group                                         spot urine   Japan      52            62.4       27       25     0%               24          8.8 ± 0.5 \*\*                                                                            ng/mg                       8                                1
  \[[@B71-ijms-21-03743]\]   Male group                                            spot urine   Japan      276           42.1       0        276    NA               23.8        8.8 ± 0.2 \*\*                                                                            ng/mg                       8                                1
  \[[@B71-ijms-21-03743]\]   Female group                                          spot urine   Japan      445           42.7       445      0      NA               21.9        9.8 ± 0.2 \*\*                                                                            ng/mg                       9                                2
  \[[@B72-ijms-21-03743]\]   Male healthy population                               spot urine   Japan      142           43.6       0        142    31%              22.4        11.5 ± 5.2 \*                                                                             ng/mg                       10                               2
  \[[@B72-ijms-21-03743]\]   Female healthy population                             spot urine   Japan      136           43.4       136      0      52.2%            23.8        9.4 ± 3.4 \*                                                                              ng/mg                       9                                1
  \[[@B73-ijms-21-03743]\]   Control group                                         spot urine   USA        43            32.6       43       0      0%               23.2        6.31 ± 2.49 \*                                                                            ng/mg                       6                                1
  \[[@B74-ijms-21-03743]\]   Male group                                            spot urine   Japan      323           42         0        323    42.7%            23.7        8.85 ± 3.29                                                                               ng/mg                       8                                1
  \[[@B74-ijms-21-03743]\]   Female group                                          spot urine   Japan      443           42.7       443      0      13.5%            21.9        9.89 ± 4.54 \*                                                                            ng/mg                       9                                2
  \[[@B75-ijms-21-03743]\]   Green tea catechin-no exercise group baseline value   spot urine   Japan      8             22.4       0        8      0%               \>18 \<25   15.9 ± 3.6 \*                                                                             ng/mg                       16                               1
  \[[@B75-ijms-21-03743]\]   Green tea catechin-exercise group baseline value      spot urine   Japan      8             21.1       0        8      0%               \>18 \<25   22.9 ± 7.9 \*                                                                             ng/mg                       22                               1
  \[[@B75-ijms-21-03743]\]   Placebo group                                         spot urine   Japan      8             21.1       0        8      0%               \>18 \<25   18 ± 6.2 \*                                                                               ng/mg                       17                               1
  \[[@B76-ijms-21-03743]\]   Men group                                             spot urine   Japan      272           43.5       0        272    60.7%            23.7        8.86 ± 3.36 \*                                       2.13--21.87                          μg/g                        8                                1
  \[[@B76-ijms-21-03743]\]   Women group                                           spot urine   Japan      295           40.3       295      0      15.6%            21.7        9.25 ± 4.03 \*                                       0.05--25.56                          μg/g                        8                                2
  \[[@B77-ijms-21-03743]\]   Baseline value 50km group                             spot urine   Italy      6             41.83      NA       NA     0%               21.08       4.38 ± 1.16 \*                                                                            ng/mg                       4                                1
  \[[@B78-ijms-21-03743]\]   Summer Non heating season                             spot urine   China      34            47.9       34       0      0%               23.2        12.7 ± 4.7 \*                                        2.60, 25.8     13.6                  ng/mg                       9                                2
  \[[@B79-ijms-21-03743]\]   Healthy volunteers Young group                        spot urine   Turkey     30            41.6       22       8      0%               22.1        3.24 ± 1.54 \*                                                                            ng/mg                       3                                2
  \[[@B79-ijms-21-03743]\]   Healthy volunteers Elderly group                      spot urine   Turkey     30            69.1       20       10     0%               23.6        5.74 ± 2.68 \*                                                                            ng/mg                       5                                2
  \[[@B80-ijms-21-03743]\]   Baseline value                                        spot urine   China      25            20.9       12       13     0%               20.67       3765.63 ± 958.14 \*                                                                       ng/mmol                     32                               1
  \[[@B15-ijms-21-03743]\]   Women group                                           spot urine   Italy      33            30         33       0      29%              20.7                                                3.68--7.20                  5.21                  ng/mg                       4                                2
  \[[@B81-ijms-21-03743]\]   Non exposed group                                     spot urine   China      143           27.89      100      43     8%               21.03       17.36 ± 13.5 \*                                                                           ng/mg                       14                               2

\* SD; \*\* SEM.

ijms-21-03743-t005_Table 5

###### 

References for urinary 8-OHdG concentrations measured and computed GM (ng/mg creatinine) with immunological techniques in healthy (mean BMI \> 25 and no known disease), adult (18+ years) participants.

  Reference                  Study Group                         Sample       Country   Sample Size   Mean Age   Female   Male   Smoking Status   MeanBMI   AM                  IQR          Range        Median   Units (8-OHdG/Creatinine)   Computed GM (ng/mg Creatinine)   GSD
  -------------------------- ----------------------------------- ------------ --------- ------------- ---------- -------- ------ ---------------- --------- ------------------- ------------ ------------ -------- --------------------------- -------------------------------- -----
  \[[@B82-ijms-21-03743]\]   Cocorit communities                 spot urine   Mexico    10            45.9       5        5      30%              27        8.2 ± 4.3 \*                                           μg/g                        7                                2
  \[[@B82-ijms-21-03743]\]   Pueblo Yaqui communities            spot urine   Mexico    15            35.3       9        6      7%               26.7      5.7 ± 2.9 \*                                           μg/g                        5                                2
  \[[@B82-ijms-21-03743]\]   Campo 47                            spot urine   Mexico    15            39.5       10       5      40%              29.8      5.7 ± 3.3 \*                                           μg/g                        5                                2
  \[[@B83-ijms-21-03743]\]   Control group                       spot urine   UK        61            28.4       61       0      9%               26        39.83 ± 2.92 \*\*                                      ng/mg                       35                               2
  \[[@B55-ijms-21-03743]\]   Healthy older group                 24 h urine   Canada    12            71.8       0        12     0%               28.8      7714 ± 1402 \*                                         ng/g                        8                                1
  \[[@B84-ijms-21-03743]\]   Water group baseline value          spot urine   USA       42            18--79     32       10     100%             25.9      8.7 ± 1.3 \*\*                                         ng/mg                       5                                3
  \[[@B84-ijms-21-03743]\]   Green tea group baseline value      spot urine   USA       35            18--79     27       8      100%             26.5      10.8 ± 1.3 \*\*                                        ng/mg                       9                                2
  \[[@B84-ijms-21-03743]\]   Black tea baseline value            spot urine   USA       43            18--79     31       12     100%             26.7      9.5 ± 2.1 \*\*                                         ng/mg                       6                                2
  \[[@B85-ijms-21-03743]\]   Water group baseline value          spot urine   USA       45            49.8       32       13     100%             26.9      9.5 ± 1.3 \*\*                                         ng/mg                       6                                3
  \[[@B85-ijms-21-03743]\]   Black tea baseline value            spot urine   USA       46            52.1       34       12     100%             27.2      10.8 ± 2.5 \*\*                                        ng/mg                       7                                2
  \[[@B85-ijms-21-03743]\]   Green tea group baseline value      spot urine   USA       42            51.6       32       10     100%             27.2      8.7 ± 1.8 \*\*                                         ng/mg                       5                                3
  \[[@B86-ijms-21-03743]\]   Placebo group baseline value        24 h urine   USA       47            58.1       23       24     0%               28.9      17.6 ± 10.4 \*                                         ng/mg                       15                               2
  \[[@B86-ijms-21-03743]\]   Vit C group baseline value          24 h urine   USA       46            61.2       26       20     0%               28.7      19.3 ± 9.3 \*                                          ng/mg                       17                               2
  \[[@B86-ijms-21-03743]\]   Vit E group baseline value          24 h urine   USA       45            55.5       29       16     0%               28.6      16.5 ± 8.4 \*                                          ng/mg                       15                               2
  \[[@B86-ijms-21-03743]\]   Vit C + Vit E baseline value        24 h urine   USA       46            57.7       24       22     0%               28.9      17.7 ± 9.5 \*                                          ng/mg                       16                               2
  \[[@B87-ijms-21-03743]\]   Control group                       24 h urine   Finland   100           65         46       54     18%              27.7      24.3 ± 15.2 \*                                         ng/mg                       21                               2
  \[[@B88-ijms-21-03743]\]   Control group                       spot urine   Taiwan    27            49         0        27     55.6%            25.8      5 ± 4.92 \*                                            µg/g                        4                                2
  \[[@B89-ijms-21-03743]\]   All population                      spot urine   Japan     90            52         60       30     0%               25.2                          5.8--23.2    0.90--48.0   9.3      ng/mg                       9                                3
  \[[@B90-ijms-21-03743]\]   Baseline value                      spot urine   Canada    28            68.5       NA       NA     0%               27.1      10783 ± 5856 \*                                        ng/g                        9                                2
  \[[@B91-ijms-21-03743]\]   control group baseline              spot urine   Spain     23            30.42      23       0      0%               25.32     9.29 ± 0.69 \*\*                                       ng/mg                       9                                1
  \[[@B91-ijms-21-03743]\]   DHA group baseline                  spot urine   Spain     23            29.97      23       0      0%               25.62     9.81 ± 0.79 \*\*                                       ng/mg                       9                                1
  \[[@B92-ijms-21-03743]\]   Placebo group men                   24 h urine   Canada    8             74.8       0        8      0%               25.9      8329 ± 3032 \*                                         ng/g                        8                                1
  \[[@B92-ijms-21-03743]\]   Placebo group women                 24 h urine   Canada    10            68.3       10       0      0%               25.2      11622 ± 4379 \*                                        ng/g                        7                                1
  \[[@B92-ijms-21-03743]\]   Intervention group men baseline     24 h urine   Canada    11            71.8       0        11     0%               27.8      7245 ± 2703 \*                                         ng/g                        11                               1
  \[[@B92-ijms-21-03743]\]   Intervention group women baseline   24 h urine   Canada    10            69.5       10       0      0%               25.5      7942 ± 3071 \*                                         ng/g                        7                                1
  \[[@B15-ijms-21-03743]\]   Men group early morning             spot urine   Italy     22            34         0        22     38.1%            25.3                          2.76--5.25                3.76     ng/mg                       5                                2

\* SD; \*\* SEM.

[^1]: Both are last authors.
